Molecule Name |
DB00460
|
DrugBank Groups |
Approved
|
Cluster No |
262
|
Smiles |
O=C(OC)C1(=CC=C2(C=3(C=C6(NC(=CC=5(C(C)=C(C(=CC=4(NC(C=C(C2(C1C(=O)OC)(C))N=3)=C(C=4(CCC(=O)OC))C))N=5)CCC(=O)O))C(=C6C)C=C))))
|
Download |
mol2, pdbqt
|
TPSA |
168,74
|
Non-H Atoms |
53
|
Non-C/H Atoms |
12
|
Metal-Atoms |
0
|
Electronegative Atoms |
12
|
Stereo Centers |
2
|
Rotatable Bonds |
12
|
Rings Closures |
6
|
Small Rings |
5
|
Aromatic Rings |
1
|
Aromatic Atoms |
5
|
sp3-Atoms |
17
|
Symmetric atoms |
0
|
cLogS |
-6,13
|
MW |
718,804
|
cLogP |
4,4733
|
HBA |
12
|
HBD |
3
|
Ro5 violations |
2
|
Druglikeness |
-8,6414
|
DrugScore |
8,11333560162368E-02
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
high
|
Blood-Brain Barrier |
BBB+
|
Human Intestinal Absorption |
HIA-
|
Caco-2 Permeability |
Caco2-
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Non-inhibitor
|
P-glycoprotein Inhibitor 2 |
Non-inhibitor
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Aqueous solubility |
-3,3427
|
Caco-2 Permeability 2 |
0,4384
|
Subcellular localization |
Mitochondria
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 2D6 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 1A2 Inhibitor |
Inhibitor
|
CYP450 2C9 Inhibitor |
Inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 3A4 Inhibitor |
Non-inhibitor
|
CYP Inhibitory Promiscuity |
High CYP Inhibitory Promiscuity
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition 2 |
Non-inhibitor
|
AMES Toxicity |
Non AMES toxic
|
Carcinogens |
Non-carcinogens
|
Fish Toxicity |
High FHMT
|
Fish Toxicity (pLC50, mg/L) |
0,8318
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity (pIGC50, ug/L) |
0,7324
|
Honey Bee Toxicity |
Low HBT
|
Biodegradation |
Not ready biodegradable
|
Acute Oral Toxicity |
III
|
Rat Acute Toxicity (LD50, mol/kg) |
2,6756
|
Carcinogenicity (Three-class) |
Non-required
|